Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 005329107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
WuXi PharmaTech Healthcare Fund I L.P.
13G/A
Amendment 4
|
3.5% |
8/14/2026
Event 6/30/2026
|
|
| WuXi PharmaTech Healthcare Fund I L.P. | 3.5% | ||
| WuXi AppTec Co., Ltd. | 3.5% | ||
|
Peter Luo
13D/A
Amendment 4
|
11.2% |
6/8/2026
Event 6/5/2026
|
|
| Peter Luo | 7.1% | ||
| HAN 2020 Irrevocable Trust | 11.2% | ||
|
WuXi PharmaTech Healthcare Fund I L.P.
13G/A
Amendment 3
|
5.9% |
5/15/2026
Event 3/31/2026
|
|
| WuXi PharmaTech Healthcare Fund I L.P. | 5.9% | ||
| WuXi AppTec Co., Ltd. | 5.9% | ||
| Janus Henderson Group PLC 13G | 10.1% |
5/7/2026
Event 4/30/2026
|
|
| Chernett Jorey 13G | 5.1% |
3/18/2026
Event 3/16/2026
|
|
|
General Atlantic, L.P.
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| General Atlantic Singapore Fund Pte. Ltd. | 0% | ||
| General Atlantic Singapore Interholdco Ltd. | 0% | ||
| General Atlantic Partners (Bermuda) IV, L.P. | 0% | ||
| General Atlantic Partners (Bermuda) EU, L.P. | 0% | ||
| General Atlantic GenPar (Bermuda), L.P. | 0% | ||
| GAP (Bermuda) L.P. | 0% | ||
| General Atlantic, L.P. | 0% | ||
| GAP Coinvestments III, LLC | 0% | ||
| GAP Coinvestments IV, LLC | 0% | ||
| GAP Coinvestments V, LLC | 0% | ||
| GAP Coinvestments CDA, L.P. | 0% | ||
| General Atlantic Partners (Lux) SCSp | 0% | ||
| General Atlantic GenPar (Lux) SCSp | 0% | ||
| General Atlantic (Lux) S.a r.l. | 0% | ||
| General Atlantic Singapore AI Pte. Ltd. | 0% | ||
|
Smith Vincent C
13G/A
Amendment 1
|
8.7% |
1/29/2026
Event 12/31/2025
|
|
| Smith Vincent C | 8.7% | ||
| The Vincent C. Smith, Jr. 2025 Annuity Trust | 6.1% | ||
| VCS Master Holdings GP | 1.0% | ||
|
WuXi PharmaTech Healthcare Fund I L.P.
13G/A
Amendment 2
|
7.0% |
11/14/2025
Event 9/30/2025
|
|
| WuXi PharmaTech Healthcare Fund I L.P. | 7.0% | ||
| WuXi AppTec Co., Ltd. | 7.0% | ||
|
Panacea Innovation Ltd
13G/A
Amendment 3
|
3.8% |
11/14/2025
Event 9/30/2025
|
|
| Panacea Venture Healthcare Fund II, L.P. | 3.8% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 3.8% | ||
| Panacea Innovation Limited | 3.8% | ||
| James Huang | 3.8% | ||
|
FMR LLC
13G/A
Amendment 4
|
0.9% |
7/2/2025
Event 6/30/2025
|
|
| FMR LLC | 0.9% | ||
| Abigail P. Johnson | 0.9% | ||
|
WuXi PharmaTech Healthcare Fund I L.P.
13G/A
Amendment 1
|
8.5% |
5/15/2025
Event 3/31/2025
|
|
| WuXi PharmaTech Healthcare Fund I L.P. | 8.5% | ||
| WuXi AppTec Co., Ltd. | 8.5% | ||
|
FIL Ltd
13G/A
Amendment 2
|
1.8% |
5/12/2025
Event 3/31/2025
|
|
| FIL Limited | 1.8% | ||
| Pandanus Partners, L.P. | 1.8% | ||
| Pandanus Associates, Inc. | 1.8% | ||
|
Peter Luo
13D/A
Amendment 3
|
15.6% |
2/19/2025
Event 1/25/2025
|
|
| Peter Luo | 6.1% | ||
| HAN 2020 Irrevocable Trust | 15.6% | ||
|
Panacea Innovation Ltd
13G/A
Amendment 2
|
5.5% |
2/14/2025
Event 12/31/2024
|
|
| Panacea Venture Healthcare Fund II, L.P. | 5.5% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 5.5% | ||
| Panacea Innovation Limited | 5.5% | ||
| James Huang | 5.5% | ||
|
FIL Ltd
13G/A
Amendment 1
|
7.8% |
2/12/2025
Event 12/31/2024
|
|
| FIL Limited | 7.8% | ||
| Pandanus Partners, L.P. | 7.8% | ||
| Pandanus Associates, Inc. | 7.8% | ||
|
Smith Vincent C
13G
|
6.9% |
2/4/2025
Event 12/31/2024
|
|
| Smith Vincent C | 6.9% | ||
| Red Beard Holdings, LLC | 5.6% | ||
| VCS Master Holdings GP | 1.0% | ||
|
OT Healthcare Fund I, LLC
13G/A
Amendment 1
|
8.1% |
2/3/2025
Event 9/6/2024
|
|
| OT Healthcare Fund I, LLC | |||
| OT Management, LLC | 8.1% | ||
| Nichola Eliovits | 8.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 35 | 19.3 M | $81.0 M |
| 2026 Q1 | 25 | 3.30 M | $9.70 M |
| 2025 Q4 | 17 | 3.09 M | $6.03 M |
| 2025 Q3 | 17 | 5.72 M | $11.3 M |
| 2025 Q2 | 17 | 6.08 M | $11.9 M |
| 2025 Q1 | 15 | 7.62 M | $11.6 M |
| 2024 Q4 | 16 | 10.4 M | $20.3 M |
| 2024 Q3 | 15 | 11.4 M | $25.9 M |
| 2024 Q2 | 16 | 11.3 M | $34.0 M |
| 2024 Q1 | 20 | 12.5 M | $34.8 M |
| 2023 Q4 | 13 | 7.27 M | $15.8 M |
| 2023 Q3 | 11 | 4.10 M | $6.16 M |
| 2023 Q2 | 11 | 4.11 M | $6.02 M |
| 2023 Q1 | 12 | 4.19 M | $6.02 M |
| 2022 Q4 | 10 | 4.22 M | $5.58 M |
| 2022 Q3 | 12 | 5.94 M | $7.60 M |
| 2022 Q2 | 16 | 7.53 M | $15.4 M |
| 2022 Q1 | 16 | 8.39 M | $29.7 M |
| 2021 Q4 | 17 | 8.37 M | $67.3 M |
| 2021 Q3 | 20 | 8.79 M | $127 M |
| 2021 Q2 | 17 | 5.94 M | $80.5 M |
| 2021 Q1 | 28 | 6.44 M | $116 M |